EUVIMEDEUVIMED entdecken
Übersichtsarbeit

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials

Faiez Zannad iD, Arun J Sanyal, Javed Butler, João Pedro Ferreira, Nicolas Girerd, Veronica Miller, Ambarish Pandey, Chirag R Parikh, Vlad Ratziu, Zobair M Younossi iD, Stephen A Harrison

Journal of Internal Medicine · 2024-07 · 296 (1) · 24-38

DOI: 10.1111/joim.13793 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, online erschienen am 13.05.2024. Verfasst von Faiez Zannad und 10 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lorraine, Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy, Nancy, Fran…. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Steatotic liver disease (SLD) is a worldwide public health problem, causing considerable morbidity and mortality. Patients with SLD are at increased risk for major adverse cardiovascular (CV) events, type 2 diabetes mellitus and chronic kidney disease. Conversely, patients with cardiometabolic conditions have a high prevalence of SLD. In addition to epidemiological evidence linking many of these conditions, there is evidence of shared pathophysiological processes. In December 2022, a unique multi‐stakeholder, multi‐specialty meeting, called MOSAIC (Metabolic multi Organ Science Accelerating Innovation in Clinical Trials) was convened to foster collaboration across metabolic, hepatology, nephrology and CV disorders. One of the goals of the meeting was to consider approaches to drug development that would speed regulatory approval of treatments for multiple disorders by combining liver and cardiorenal endpoints within a single study. Non‐invasive tests, including biomarkers and imaging, are needed in hepatic and cardiorenal trials. They can be used as trial endpoints, to enrich trial populations, to diagnose and risk stratify patients and to assess treatment efficacy and safety. Although they are used in proof of concept and phase 2 trials, they are often not acceptable for regulatory approval of therapies. The challenge is defining the optimal combination of biomarkers, imaging and morbidity/mortality outcomes and ensuring that they are included in future trials while minimizing the burden on patients, trialists and trial sponsors. This paper provides an overview of some of the wide array of CV, liver and kidney measurements that were discussed at the MOSAIC meeting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicHumansCardiovascular DiseasesFatty LiverBiomarkersRenal Insufficiency, ChronicDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

cardiovascular diseasemetabolic dysfunction‐associated steatotic liver diseasenon‐invasive testssteatohepatitissteatotic liver disease

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Université de Lorraine, Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy, Nancy, France.
  • Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
  • Baylor Scott and White Research Institute, Dallas, Texas, USA.
  • University of Mississippi, Jackson, Mississippi, USA.
  • UnIC@RISE, Cardiovascular Research and Development Center, Department Surgery Physiology, University of Porto, Porto, Portugal.
  • Centre d'Investigations Cliniques Plurithématique 1433, INSERM, Université de Lorraine, Nancy, France.

ORCID-Profile: Faiez Zannad, Zobair M Younossi

Zitieren

APA

Zannad, F., Sanyal, A. J., Butler, J., Ferreira, J. P., Girerd, N., Miller, V., Pandey, A., Parikh, C. R., Ratziu, V., Younossi, Z. M., & Harrison, S. A. (2024). MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. Journal of Internal Medicine, 296(1), 24-38. https://doi.org/10.1111/joim.13793

Vancouver

Zannad F, Sanyal AJ, Butler J, Ferreira JP, Girerd N, Miller V, et al. MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. Journal of Internal Medicine. 2024;296(1):24-38. doi:10.1111/joim.13793

BibTeX
@article{Zannad2024,
  author = {Zannad, Faiez and Sanyal, Arun J and Butler, Javed and Ferreira, João Pedro and Girerd, Nicolas and Miller, Veronica and Pandey, Ambarish and Parikh, Chirag R and Ratziu, Vlad and Younossi, Zobair M and Harrison, Stephen A},
  title = {MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials},
  journal = {Journal of Internal Medicine},
  year = {2024},
  volume = {296},
  number = {1},
  pages = {24--38},
  doi = {10.1111/joim.13793}
}
Kostenlos starten →